Auven Therapeutics

Auven Therapeutics is a private biotechnology company focused on developing and commercializing innovative therapies, particularly in the areas of Oncology, Cardiology, and Neurology. The company was founded by Stephen Evans-Freke and Dr. Peter B. Corr, with the goal of creating a unique investment model that combines the benefits of private equity and venture capital. Auven Therapeutics has established partnerships with various organizations, including Harvard University, Massachusetts Institute of Technology, and Stanford University, to advance its research and development efforts. The company's approach is centered around identifying and supporting promising Biotech companies, such as Gilead Sciences, Amgen, and Biogen, and working with renowned researchers like Dr. James Allison and Dr. Tasuku Honjo.

● Overview

Auven Therapeutics operates at the intersection of Biotechnology, Pharmaceuticals, and Healthcare, with a focus on developing novel treatments for diseases like Cancer, Alzheimer's disease, and Parkinson's disease. The company's investment strategy is guided by the expertise of its management team, which includes seasoned professionals from the Biotech and Pharmaceutical industries, such as Dr. Robert Langer and Dr. George Whitesides. Auven Therapeutics has also established relationships with leading research institutions, including National Institutes of Health, University of California, San Francisco, and Duke University, to stay at the forefront of medical innovation. By collaborating with companies like Pfizer, Merck & Co., and Johnson & Johnson, Auven Therapeutics aims to accelerate the development of groundbreaking therapies.

● History

Auven Therapeutics was founded in 2010 by Stephen Evans-Freke and Dr. Peter B. Corr, with the vision of creating a unique investment platform that would support the development of innovative therapies. The company's early investments included stakes in Biotech companies like Regeneron Pharmaceuticals and United Therapeutics, which have since become leaders in their respective fields. Over the years, Auven Therapeutics has expanded its portfolio to include investments in companies like Celgene, Gilead Sciences, and Incyte Corporation, and has established partnerships with organizations like American Cancer Society, American Heart Association, and Michael J. Fox Foundation. The company's growth has been guided by its management team, which has included experienced professionals from the Biotech and Pharmaceutical industries, such as Dr. Roy Vagelos and Dr. P. Roy Vagelos.

● Investments

Auven Therapeutics has made significant investments in a range of Biotech companies, including Seattle Genetics, Exelixis, and Alnylam Pharmaceuticals. The company's investment strategy is focused on identifying promising therapies and supporting their development through clinical trials and regulatory approvals. Auven Therapeutics has also invested in companies like Illumina, Thermo Fisher Scientific, and Agilent Technologies, which provide critical technologies and services to the Biotech and Pharmaceutical industries. By partnering with companies like Bristol-Myers Squibb, AstraZeneca, and GlaxoSmithKline, Auven Therapeutics aims to accelerate the development of innovative therapies and improve patient outcomes.

● Portfolio

Auven Therapeutics' portfolio includes a range of Biotech companies, each with its own unique focus and expertise. The company's portfolio companies are developing innovative therapies for a range of diseases, including Cancer, Infectious diseases, and Genetic disorders. Auven Therapeutics has invested in companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, which are pioneering the use of Gene editing technologies like CRISPR-Cas9. The company's portfolio also includes investments in companies like Moderna Therapeutics, BioNTech, and CureVac, which are developing innovative Vaccine technologies. By supporting these companies, Auven Therapeutics is helping to advance the development of groundbreaking therapies and improve patient outcomes.

● Management

Auven Therapeutics' management team includes experienced professionals from the Biotech and Pharmaceutical industries, such as Dr. Peter B. Corr and Stephen Evans-Freke. The company's management team has a deep understanding of the Biotech and Pharmaceutical industries, and has established relationships with leading research institutions, including Harvard University, Stanford University, and Massachusetts Institute of Technology. Auven Therapeutics' management team is guided by a commitment to advancing medical innovation and improving patient outcomes, and has established partnerships with companies like Pfizer, Merck & Co., and Johnson & Johnson to achieve these goals. The company's management team has also worked with renowned researchers like Dr. James Allison and Dr. Tasuku Honjo, and has supported the development of innovative therapies like Immunotherapy and Gene therapy.